Health
Cannabinoid Pharmacokinetics: How THC and CBD Move Through the Human Body
Understanding how cannabinoids interact with human physiology requires more than memorizing strain names or potency percentages. It demands literacy in pharmacokinetics: the study of how substances are absorbed, distributed, metabolized, and eliminated (ADME). For cannabis consumers, educators, and wellness practitioners, grasping these principles transforms guesswork into informed decision-making. Pharmacokinetics explains why the same dose can produce vastly different effects, why onset times vary by consumption method, and why individual responses are so highly personalized.
Absorption: The Gateway to Systemic Exposure
Cannabinoids are highly lipophilic, meaning they dissolve readily in fats but poorly in water. This fundamental property dictates how they enter the bloodstream. Inhalation bypasses the digestive system entirely. When vaporized or combusted, THC and CBD cross the alveolar membrane in the lungs within seconds, entering pulmonary circulation and reaching the brain in under 10 minutes. Peak plasma concentrations typically occur within 3–10 minutes, making inhalation the most predictable route for rapid onset and titration.
Oral consumption follows a completely different pathway. Ingested cannabinoids travel through the stomach and small intestine, where they must be solubilized by bile acids before absorption. This process is slow and highly variable, influenced by gastric emptying rate, meal composition, and individual gut physiology. First-pass metabolism in the liver further alters the chemical profile before systemic distribution. Sublingual administration offers a middle ground: mucosal absorption allows partial bypass of first-pass metabolism, yielding faster onset than edibles but slower than inhalation.
Distribution: Where Cannabinoids Travel and Accumulate
Once in circulation, cannabinoids distribute rapidly to highly perfused tissues, particularly the brain, liver, and adipose tissue. THC’s psychoactive effects correlate with its crossing of the blood-brain barrier, facilitated by its lipophilic nature and molecular weight (~314 Da). CBD, while less psychoactive, follows similar distribution pathways and accumulates in fatty tissues, which can influence duration of action and drug testing windows.
Importantly, cannabinoids exhibit biphasic tissue distribution. Initial plasma concentrations drop quickly as compounds sequester into fat stores, but slow release from adipose tissue can maintain low-level systemic presence for days or weeks. This explains why infrequent users may clear cannabinoids rapidly, while heavy consumers test positive long after last use. It also underscores why dosing consistency matters: accumulation can subtly shift baseline endocannabinoid tone over time.
Metabolism: The Liver’s Transformative Role
Hepatic metabolism is the primary determinant of cannabinoid duration, potency, and individual variability. THC is metabolized mainly by cytochrome P450 enzymes, particularly CYP2C9 and CYP3A4, into 11-hydroxy-THC (11-OH-THC), a metabolite with equal or greater psychoactive potency. This conversion occurs significantly during oral consumption, explaining why edibles often feel stronger and longer-lasting than inhaled equivalents despite identical labeled THC content.
CBD undergoes extensive hepatic metabolism as well, primarily via CYP3A4 and CYP2C19, producing metabolites like 7-hydroxy-CBD and 7-carboxy-CBD. These metabolites are generally less active but contribute to prolonged systemic exposure. Individual metabolic capacity varies widely due to genetic polymorphisms, age, liver health, diet, and concurrent medication use. Two people consuming identical doses may experience dramatically different effects simply due to enzymatic efficiency.
Elimination: Half-Life, Clearance, and Detection Windows
Elimination occurs primarily through feces and urine, with minor excretion via sweat and breath. THC’s terminal half-life ranges from 20–30 hours in occasional users to 5–13 days in chronic consumers, reflecting adipose storage and slow release. CBD’s half-life is typically shorter (18–32 hours) but can extend with frequent dosing or formulation changes.
Detection windows in drug testing depend on assay sensitivity, consumption frequency, body composition, and metabolic rate. Urine tests typically detect THC-COOH (the primary inactive metabolite) for 3–30 days post-use. Blood tests capture active compounds for hours to a few days. Hair assays can trace exposure for months but are prone to external contamination. Understanding these timelines is essential for workplace compliance, medical transparency, and personal planning.
Practical Educational Takeaways
Pharmacokinetic literacy empowers consumers to:
- Match consumption methods to desired onset and duration
- Recognize why oral dosing requires patience and lower starting amounts
- Understand individual variability without assuming product inconsistency
- Navigate drug testing awareness with realistic expectations
- Communicate more effectively with healthcare providers about timing, dosing, and metabolic considerations
Cannabis education isn’t complete without ADME fundamentals. When consumers understand how cannabinoids move through the body, they move beyond trial-and-error consumption into intentional, informed practice. The next generation of cannabis literacy won’t just measure potency. It will measure physiology.